Similarly, antibody therapies such as Rituximab (Rituxan), an anti-CD20 monoclonal antibody for non-Hodgkin lymphoma; Cetuximab (Erbitux), an epidermal growth factor receptor (EGFR)-binding antibody for colorectal and head and neck cancer; Trastuzumab (Herceptin), a monoclonal antibody that allows targeted therapy in HER2 positive breast cancer; and Bevacizumab (Avastin), a recombinant humanized antibody against vascular endothelial growth factor (VEGF) for metastatic colorectal cancer are promising. This evidence concerns the gene EGFR and head and neck cancer.